(NASDAQ: OPHI) Collplant Biotechnologies's forecast annual revenue growth rate of 540.21% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 42.44%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.54%.
Collplant Biotechnologies's revenue in 2026 is $318,000.On average, 4 Wall Street analysts forecast OPHI's revenue for 2026 to be $11,658,793, with the lowest OPHI revenue forecast at $2,830,926, and the highest OPHI revenue forecast at $20,969,073. On average, 4 Wall Street analysts forecast OPHI's revenue for 2027 to be $16,092,948, with the lowest OPHI revenue forecast at $3,538,658, and the highest OPHI revenue forecast at $29,340,526.
In 2028, OPHI is forecast to generate $28,725,233 in revenue, with the lowest revenue forecast at $27,598,640 and the highest revenue forecast at $29,570,178.